{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:04:44Z","timestamp":1772780684825,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,25]]},"DOI":"10.7759\/cureus.35463","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T22:49:26Z","timestamp":1677365366000},"source":"Crossref","is-referenced-by-count":6,"title":["A Systematic Review of Lipid Management in Secondary Prevention and Comparison of International Lipid Management Pathways"],"prefix":"10.7759","author":[{"given":"Zahid","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amresh","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif","family":"Yousif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.103.23.2768","article-title":"In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now","volume":"103","author":"Fonarow GC","year":"2001","unstructured":"Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Circulation. 2001, 103:2768-70. 10.1161\/01.cir.103.23.2768","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018897","article-title":"Lipid management in patients presenting with acute coronary syndromes: a review","volume":"9","author":"Claessen BE","year":"2020","unstructured":"Claessen BE, Guedeney P, Gibson CM, Angiolillo DJ, Cao D, Lepor N, Mehran R. Lipid management in patients presenting with acute coronary syndromes: a review. J Am Heart Assoc. 2020, 9:e018897. 10.1161\/JAHA.120.018897","journal-title":"J Am Heart Assoc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2021.01.010","article-title":"Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives","volume":"42","author":"Alings M","year":"2020","unstructured":"Alings M, Descamps O, Guillon B, et al.. Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. Atheroscler Suppl. 2020, 42:e59-64. 10.1016\/j.atherosclerosissup.2021.01.010","journal-title":"Atheroscler Suppl"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al.. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020, 41:111-88. 10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.07.007","article-title":"Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study","volume":"308","author":"Gulizia MM","year":"2020","unstructured":"Gulizia MM, Maggioni AP, Abrignani MG, et al.. Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study. Atherosclerosis. 2020, 308:32-8. 10.1016\/j.atherosclerosis.2020.07.007","journal-title":"Atherosclerosis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.05.037","article-title":"A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy)","volume":"277","author":"Descamps OS","year":"2018","unstructured":"Descamps OS, Van Caenegem O, Hermans MP, et al.. A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy). Atherosclerosis. 2018, 277:369-76. 10.1016\/j.atherosclerosis.2018.05.037","journal-title":"Atherosclerosis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa034","article-title":"Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study","volume":"41","author":"Allahyari A","year":"2020","unstructured":"Allahyari A, Jernberg T, Hagstr\u00f6m E, Leosdottir M, Lundman P, Ueda P. Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J. 2020, 41:3900-9. 10.1093\/eurheartj\/ehaa034","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2023.107141","article-title":"The effect of the 2019 ESC\/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project","volume":"148","author":"Laufs U","year":"2023","unstructured":"Laufs U, Catapano AL, De Caterina R, Schiele F, Sionis A, Zaman A, Jukema JW. The effect of the 2019 ESC\/EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS EuroPath IV project. Vascul Pharmacol. 2023, 148:107141. 10.1016\/j.vph.2023.107141","journal-title":"Vascul Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01616-9","article-title":"Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study","volume":"20","author":"Kristensen MS","year":"2020","unstructured":"Kristensen MS, Green A, Nybo M, et al.. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study. BMC Cardiovasc Disord. 2020, 20:336. 10.1186\/s12872-020-01616-9","journal-title":"BMC Cardiovasc Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2048872620912639","article-title":"An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals","volume":"9","author":"Buonvino C","year":"2020","unstructured":"Buonvino C, Chopard R, Guillon B, et al.. An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals. Eur Heart J Acute Cardiovasc Care. 2020, 9:879-87. 10.1177\/2048872620912639","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/150321","article-title":"Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper","volume":"18","author":"Sabouret P","year":"2022","unstructured":"Sabouret P, Lemesle G, Bellemain-Appaix A, et al.. Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper. Arch Med Sci. 2022, 18:839-54. 10.5114\/aoms\/150321","journal-title":"Arch Med Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-016-0993-x","article-title":"Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update","volume":"128 Suppl 2","author":"Toplak H","year":"2016","unstructured":"Toplak H, Ludvik B, Lechleitner M, et al.. Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update. Wien Klin Wochenschr. 2016, 128 Suppl 2:S216-28. 10.1007\/s00508-016-0993-x","journal-title":"Wien Klin Wochenschr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2022.07.009","article-title":"Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome","volume":"16","author":"Garc\u00eda RV","year":"2022","unstructured":"Garc\u00eda RV, Garc\u00eda JE, Navas WD, Salmer\u00f3n DM, Mateos DB. Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome. J Clin Lipidol. 2022, 16:635-42. 10.1016\/j.jacl.2022.07.009","journal-title":"J Clin Lipidol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1474515119831511","article-title":"Efficacy of a nurse-led lipid-lowering secondary prevention intervention in patients hospitalized for ischemic heart disease: A pilot randomized controlled trial","volume":"18","author":"Ruiz-Bustillo S","year":"2019","unstructured":"Ruiz-Bustillo S, Ivern C, Badosa N, et al.. Efficacy of a nurse-led lipid-lowering secondary prevention intervention in patients hospitalized for ischemic heart disease: A pilot randomized controlled trial. Eur J Cardiovasc Nurs. 2019, 18:366-74. 10.1177\/1474515119831511","journal-title":"Eur J Cardiovasc Nurs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.23736\/S0031-0808.22.04777-2","article-title":"Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice","author":"Sabouret P","year":"2022","unstructured":"Sabouret P, Puymirat E, Kownator S, et al.. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice. Panminerva Med. 2022, 10.23736\/S0031-0808.22.04777-2","journal-title":"Panminerva Med"},{"key":"ref16","unstructured":"Cardiovascular disease. risk assessment and reduction, including lipid modification. (2014). Accessed: January 22, 2023: https:\/\/www.nice.org.uk\/guidance\/cg181\/chapter\/Recommendations."},{"key":"ref17","unstructured":"AAC publishes updated clinical pathway for lipid management. (2022). Accessed. January 15, 2023: https:\/\/www.heartuk.org.uk\/news\/latest\/post\/168-aac-publishes-updated-clinical-pathway-for-lipid-management."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer G","year":"2019","unstructured":"De Backer G, Jankowski P, Kotseva K, et al.. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019, 285:135-46. 10.1016\/j.atherosclerosis.2019.03.014","journal-title":"Atherosclerosis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2019021","article-title":"Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II","volume":"60","author":"Poh KK","year":"2019","unstructured":"Poh KK, Chin CT, Tong KL, et al.. Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the Dyslipidemia International Study II. Singapore Med J. 2019, 60:454-62. 10.11622\/smedj.2019021","journal-title":"Singapore Med J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23725","article-title":"Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II","volume":"44","author":"Gong Y","year":"2021","unstructured":"Gong Y, Li X, Ma X, et al.. Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II. Clin Cardiol. 2021, 44:1575-85. 10.1002\/clc.23725","journal-title":"Clin Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/cp.cp_20_20","article-title":"Expert consensus on clinical pathway of blood lipid management in patients with acute coronary syndrome: Chinese Medical Doctor Association, Expert Group of Clinical Pathway of Lipid Management in Patients With Acute Coronary Syndrome","volume":"5","author":"Chinese Medical Doctor Association","year":"2020","unstructured":"Chinese Medical Doctor Association, Expert Group of Clinical Pathway of Lipid Management in Patients With Acute Coronary Syndrome. Expert consensus on clinical pathway of blood lipid management in patients with acute coronary syndrome: Chinese Medical Doctor Association, Expert Group of Clinical Pathway of Lipid Management in Patients With Acute Coronary Syndrome. Cardiol Plus. 2020, 5:130-8. 10.4103\/cp.cp_20_20","journal-title":"Cardiol Plus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.08.013","article-title":"Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II","volume":"266","author":"Gitt AK","year":"2017","unstructured":"Gitt AK, Lautsch D, Ferri\u00e8res J, et al.. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Atherosclerosis. 2017, 266:158-66. 10.1016\/j.atherosclerosis.2017.08.013","journal-title":"Atherosclerosis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2019.10.015","article-title":"ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand","volume":"14","author":"Han Y","year":"2020","unstructured":"Han Y, Chen J, Chopra VK, et al.. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. J Clin Lipidol. 2020, 14:98-108.e8. 10.1016\/j.jacl.2019.10.015","journal-title":"J Clin Lipidol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23623","article-title":"Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries","volume":"44","author":"Navar AM","year":"2021","unstructured":"Navar AM, Matskeplishvili ST, Urina-Triana M, et al.. Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries. Clin Cardiol. 2021, 44:955-62. 10.1002\/clc.23623","journal-title":"Clin Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2021.01.009","article-title":"Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project","volume":"42","author":"Landmesser U","year":"2020","unstructured":"Landmesser U, Pirillo A, Farnier M, et al.. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. Atheroscler Suppl. 2020, 42:e49-58. 10.1016\/j.atherosclerosissup.2021.01.009","journal-title":"Atheroscler Suppl"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.12035","article-title":"Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis","volume":"210","author":"Brieger D","year":"2019","unstructured":"Brieger D, D'Souza M, Hyun K, Weaver JC, Kritharides L. Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. Med J Aust. 2019, 210:80-5. 10.5694\/mja2.12035","journal-title":"Med J Aust"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5837\/bjc.2022.034","article-title":"Evaluation of a lipid management pathway within a local cardiac rehabilitation service","volume":"29","author":"Jones C","year":"2022","unstructured":"Jones C. Evaluation of a lipid management pathway within a local cardiac rehabilitation service. Br J Cardiol. 2022, 29:137-40. 10.5837\/bjc.2022.034","journal-title":"Br J Cardiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine MS","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al.. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017, 376:1713-22. 10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz GG","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al.. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018, 379:2097-107. 10.1056\/NEJMoa1801174","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/130842-a-systematic-review-of-lipid-management-in-secondary-prevention-and-comparison-of-international-lipid-management-pathways","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:24Z","timestamp":1707508464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/130842-a-systematic-review-of-lipid-management-in-secondary-prevention-and-comparison-of-international-lipid-management-pathways"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.35463","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,25]]}}}